Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Non-Small Cell Lung Cancer
Clinical trial register · Germany

Non-Small Cell Lung Cancer Trials in Germany, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5062 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:18 UTC
5062
Studies in scope
all four open statuses
2869
Recruiting now
open to new participants
983
Lead sponsors
across recruiting studies
Top sites
Berlin 32 Cologne 24 Essen 23 Esslingen am Neckar 20 Heidelberg 18
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca11 Merck Sharp & Dohme LLC8 Eli Lilly and Company6 Hoffmann-La Roche5 Bristol-Myers Squibb4 Gilead Sciences4 AbbVie3 Pfizer3 Novartis Pharmaceuticals3 BioNTech SE3 Summit Therapeutics2 University Hospital Heidelberg2 Regeneron Pharmaceuticals2 Daiichi Sankyo2 Boehringer Ingelheim2 Revolution Medicines, Inc.1 Amgen1 Pierre Fabre Medicament1 Valo Therapeutics Oy1 Exelixis1 OncoC4, Inc.1 Swiss Cancer Institute1 Razor Genomics1 Goethe University1 BioInvent International AB1 Show all 34
Site location
Berlin32 Cologne24 Essen23 Esslingen am Neckar20 Heidelberg18 Gauting18 Großhansdorf13 Hamburg10 München10 Dresden10 Chemnitz9 Halle9 Frankfurt9 Georgsmarienhütte9 Oldenburg9 Lübeck8 Frankfurt am Main8 Würzburg7 Immenhausen7 Giessen6 Kassel6 Hanover5 Düsseldorf5 Hemer5 Gera5 Show all 84
All 84 locations
Target enrolment
to

Non-Small Cell Lung Cancer trials in Germany

79 of 5062 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
158
Frankfurt am Main, Jena, Rostock
2026-11
Recruiting
Hoffmann-La Roche
Phase 3
400
Berlin, Bielefeld, Essen, Esslingen am Neckar
2026-10-06
Recruiting
Bristol-Myers Squibb
Phase 3
850
Gerlingen, Munich, Regensburg, Frankfurt am Main, Oldenburg, Cologne, Dortmund, Essen
2026-09-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Münster, Hamburg
2026-06-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
Heidelberg, Bochum, Mainz, Gera
2026-05-04
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Freiburg im Breisgau, Frankfurt am Main, Düsseldorf
2026-01-30
Recruiting
Boehringer Ingelheim
Phase 3
400
Berlin, Cologne, Esslingen am Neckar, Frankfurt, Gauting, Großhansdorf, Heidelberg, Oldenburg
2026-01-16
Recruiting
ETOP IBCSG Partners Foundation
Phase 3
390
Buch, Essen, München, Oldenburg
2026-01-12
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
München, Frankfurt am Main, Kassel, Georgsmarienhütte, Chemnitz, Halle, Lübeck, Berlin
2026-01-06
Recruiting
Goethe University
Not applicable
45
Frankfurt
2026-01-02
Recruiting
AbbVie
Phase 2/3
490
Heidelberg, Würzburg, Marburg, Cologne, Jena, Hamburg
2025-12-10
Recruiting
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
NCT07261631Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Drug68Ga-NNS309
Novartis Pharmaceuticals
Phase 1
180
Essen
2025-11-24
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Esslingen am Neckar, Stuttgart, Donauwörth, Oldenburg, Cologne, Chemnitz, Kiel, Berlin
2025-11-05
Recruiting
Daiichi Sankyo
Phase 3
686
Essen, Esslingen am Neckar, Giessen, Manheim, Nordrhein Westfalen
2025-10-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Halle, Hamburg
2025-10-24
Recruiting
BioNTech SE
Phase 1/2
880
Dresden, Freiburg im Breisgau, Heidelberg
2025-09-22
Not yet open
Radiation-induced Toxicity of the Heart
NCT06986291Non-small Cell Lung Cancer, Esophageal Cancer, Breast Cancer Female
Technische Universität Dresden
Not applicable
325
Dresden
2025-08
Recruiting
Pfizer
Phase 3
714
Ulm, Gröbenzell, Traunstein, Giessen, Kassel, Koblenz, Chemnitz, Halle
2025-07-23
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Berlin, Esslingen am Neckar, Großhansdorf, Immenhausen, Velbert
2025-07-17
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Gauting, München, Giesen, Immenhausen, Göttingen, Essen, Dresden, Lübeck
2025-05-06
Recruiting
Summit Therapeutics
Phase 3
780
Chemnitz, Esslingen am Neckar, Gauting, Giesen, Halle, Herne, Karlsruhe, Minden
2025-02-27
Recruiting
BioNTech SE
Phase 2/3
1,580
Aachen, Berlin, Chemnitz, Düsseldorf, Erlangen, Esslingen am Neckar, Gauting, Gera
2025-01-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Erfurt, Jena
2024-11-21
Active, closed
Regeneron Pharmaceuticals
Phase 2
184
Kassel, Göttingen, Leipzig, Aachen
2024-11-18
Recruiting
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Essen, Esslingen am Neckar
2024-11-18
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab
Eli Lilly and Company
Phase 1
750
Frankfurt, Hamburg, Heilbronn, Würzburg
2024-10-21
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Cologne, Essen, München, Rostock
2024-10-15
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Esslingen am Neckar, Ulm, Kempten (Allgäu), München, Marburg, Hanover, Dortmund, Herne
2024-10-07
Active, closed
Hoffmann-La Roche
Phase 3
338
Berlin, Cologne, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Heidelberg, Hemer
2024-09-23
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
Berlin, Essen, Frankfurt am Main
2024-09-19
Active, closed
Amgen
Phase 1
49
Essen, Heidelberg, Würzburg
2024-09-17
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil
Eli Lilly and Company
Phase 1
630
Berlin, Dresden, Essen, München
2024-09-12
Recruiting
Gilead Sciences
Phase 1/2
334
Berlin, Cologne
2024-06-12
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Dortmund, Essen, Lübeck, Gera, Berlin
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Stuttgart, Greifswald, Bielefeld, Solingen
2024-05-24
Recruiting
AstraZeneca
Phase 3
582
Berlin, Cologne, Erfurt, Frankfurt, Göttingen, Immenhausen, Kiel, Mainz
2024-04-29
Recruiting
AstraZeneca
Phase 3
675
Berlin, Bonn, Cologne, Düsseldorf, Essen, Freiburg im Breisgau, Gauting, Georgsmarienhütte
2024-04-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Esslingen am Neckar, Regensburg, Hemer, Koblenz, Leipzig, Halle, Bad Berka, Gera
2024-04-03
Active, closed
AstraZeneca
Phase 2
142
Berlin, Cologne, Großhansdorf, Moers, Würzburg
2024-02-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Esslingen am Neckar, Gauting, Kempten (Allgäu), Regensburg, Bochum, Münster, Paderborn, Großhansdorf
2023-12-06
Active, closed
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
NCT06205706Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma
DrugPembrolizumab
BioInvent International AB
Phase 1/2
35
Essen
2023-12-04
Active, closed
Summit Therapeutics
Phase 3
1,600
Esslingen am Neckar, Frankfurt, Gauting, Giesen, Heidelberg, Jena, Kempten, Lübeck
2023-10-26
Recruiting
Pierre Fabre Medicament
Phase 1/2
345
Berlin, Dresden
2023-09-26
Active, closed
OncoC4, Inc.
Phase 3
630
Bogenhausen, Essen, Esslingen am Neckar, Immenhausen, Immenstädt, Muenchen-Gauting
2023-06-28
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
35
Essen, Heidelberg
2023-05-26
Recruiting
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
NCT05492682Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Synovial Sarcoma
DrugsCyclophosphamide·Pembrolizumab
Valo Therapeutics Oy
Phase 1
15
Frankfurt, Heidelberg, Tübingen
2023-02-02
Active, closed
Dizal Pharmaceuticals
Phase 3
324
Berlin, Gauting, Georgsmarienhütte, Heidelberg, Mainz, Oldenburg
2022-12-13
Active, closed
Hoffmann-La Roche
Phase 3
68
Berlin
2022-11-01
Active, closed
Regeneron Pharmaceuticals
Observational
509
Konstanz, München, Nuremberg, Georgsmarienhütte, Rotenburg (Wümme), Münster, Troisdorf, Leipzig
2022-10-26
Active, closed
Gilead Sciences
Phase 3
1,021
Cologne, Essen, Großhansdorf, Halle, Hamburg, Hemer, Karlsruhe, Lübeck
2022-10-12
Active, closed
University Hospital Heidelberg
Not applicable
30
Tübingen, Münich, Heidelberg
2022-06-23
Recruiting
BioNTech SE
Phase 1
320
Cologne, Frankfurt, Hamburg, Mainz
2022-06-17
Active, closed
Gilead Sciences
Phase 2
193
Berlin, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt, Gauting, Großhansdorf, Halle
2022-05-30
Recruiting
AbbVie
Phase 3
768
Heidelberg, Mannheim, Gauting, Giessen, Kassel, Dresden, Bad Berka, Berlin
2022-03-25
Active, closed
AstraZeneca
Phase 3
390
Berlin, Esslingen am Neckar, Georgsmarienhütte, Lübeck, München, Würzburg
2022-02-21
Active, closed
AstraZeneca
Phase 3
791
Berlin, Berlin-Zehlendorf, Braunschweig, Chemnitz, Cologne, Erlangen, Essen, Giessen
2022-02-18
Active, closed
AstraZeneca
Phase 3
1,051
Erfurt, Erlangen, Essen, Esslingen am Neckar, Georgsmarienhütte, Gütersloh, Hanover, Oldenburg
2022-02-07
Active, closed
Gilead Sciences
Phase 3
603
Braunschweig, Esslingen am Neckar, Hamburg, Heilbronn, Immenhausen, Kassel, Lübeck, Mannheim
2021-11-17
Active, closed
AstraZeneca
Phase 3
98
Berlin, Cologne, Hanover, München
2021-09-12
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
Guardant Health, Inc.
Observational
2,285
Hamburg, Heilbronn, Munich
2021-09-07
Recruiting
Boehringer Ingelheim
Phase 1
554
Augsburg, Cologne, Dresden, Giessen, Oldenburg
2021-07-02
Recruiting
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
DrugsImzokitug·Pumitamig·Nivolumab·Docetaxel
Bristol-Myers Squibb
Phase 1/2
1,109
Ulm, Dresden, Essen, Frankfurt, Würzburg
2021-05-27
Active, closed
Daiichi Sankyo
Phase 3
605
Berlin, Cologne, Frankfurt am Main, Freiburg im Breisgau, Gauting, Heidelberg, Hemer, Kempten
2020-12-21
Active, closed
AstraZeneca
Phase 3
358
Berlin, Bielefeld, Cologne, Esslingen a.N., Freiburg im Breisgau, Gauting, Georgsmarienhütte, Halle
2020-12-16
Active, closed
Razor Genomics
Not applicable
420
Cologne, Gauting, Georgsmarienhütte, Großhansdorf, Hanover, Lübeck, München, Oldenburg
2020-09-11
Active, closed
Swiss Cancer Institute
Phase 2
90
Tübingen
2020-07-15
Active, closed
Eli Lilly and Company
Phase 3
261
Heidelberg, Gauting, Immenstadt im Allgäu, Georgsmarienhütte, Göttingen, Cologne, Großhansdorf, Berlin
2020-02-17
Active, closed
PDC*line Pharma SAS
Phase 1/2
73
Cologne, Frankfurt am Main
2019-09-10
Active, closed
AstraZeneca
Phase 3
825
Bielefeld, Cologne, Frankfurt am Main, Immenstadt im Allgäu
2018-12-06
Active, closed
AbbVie
Phase 2
270
Mannheim, Augsburg, Giessen, Kassel, Oldenburg, Halle, Berlin, Gauting
2018-10-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Esslingen am Neckar, Immenhausen, Düsseldorf, Hemer, Rheine, Koblenz, Dresden, Leipzig
2018-04-24
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Mannheim, Augsburg, Berlin, Essen, Hamburg, Heidelberg
2018-01-26
Active, closed
AstraZeneca
Phase 2
528
Berlin, Esslingen a.N., Großhansdorf, Heidelberg
2017-12-18
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Chemnitz, Gauting, Heidelberg, Wiesbaden
2017-09-22
Active, closed
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
DrugsCabozantinib·Tecentriq·Atezolizumab
Exelixis
Phase 1
914
Düsseldorf, Tübingen
2017-09-05
Active, closed
Eli Lilly and Company
Phase 1/2
857
Würzburg, Cologne
2017-05-02
Active, closed
Xcovery Holdings, Inc.
Phase 3
290
Berlin, Großhansdorf
2016-06
Active, closed
Eli Lilly and Company
Phase 3
453
Berlin, Gera, Großhansdorf, Hamburg, Hanover, Heidelberg, Immenhausen, Nuremberg
2014-10-03
Active, closed
Tumor-specific T Cells in Lung Cancer
NCT02515760Non-small Cell Lung Cancer
University Hospital Heidelberg
Not applicable
120
Munich
2014-02
Rows per page Showing 1–79 of 79
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-germany/condition/non-small-cell-lung-cancer

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,062 studies in total at the last sync on 10 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 79 of those studies listing the condition Non-Small Cell Lung Cancer.

How many Non-Small Cell Lung Cancer trials are recruiting in Germany?

38 of the 79 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:18 UTC sync. A further 2 have not yet opened recruitment, 39 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Non-Small Cell Lung Cancer), 79 studies
PhaseStudiesRecruitingShare
Phase 3412151.9%
Phase 110612.7%
Phase 1/28510.1%
Phase 28010.1%
Not applicable516.3%
Phase 2/3435.1%
Observational212.5%
Phase 4111.3%

Most active sponsors

Lead sponsors with the most studies (Non-Small Cell Lung Cancer)
Lead sponsorStudiesRecruiting
AstraZeneca113
Merck Sharp & Dohme LLC85
Eli Lilly and Company61
Hoffmann-La Roche52
Bristol-Myers Squibb44
Gilead Sciences41
AbbVie32
BioNTech SE33
Novartis Pharmaceuticals33
Pfizer33
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.